Type 2 diabetes and fatty liver: new tests for disease tracking
Part of Hormones & metabolism clinical trials.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 80 years old.
- You have type 2 diabetes and fatty liver disease (seen on an ultrasound).
- You do not have cirrhosis (severe liver scarring) or a history of liver failure.
- You have not had heavy alcohol use (more than 2 drinks/day for men or 1 drink/day for women) in the past 10 years.
- You do not have other liver diseases like hepatitis B, hepatitis C, or autoimmune hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study follows people who have both type 2 diabetes and fatty liver disease to see how these conditions affect heart health over time. By participating, you'll help researchers learn more about lowering your risk of heart problems.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study tests a new blood test to help diagnose fatty liver disease and liver fibrosis. It aims to see how well the test works compared with a liver biopsy. Your participation could help improve diagnosis for others.
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
Hear when a new Metabolic Dysfunction-Associated Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.